Accessibility Menu
MaxCyte logo

MaxCyte(NASDAQ) MXCT

Market Cap$118.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-34%
5 Year-93%
1 Year-46%
1 Month-14%
$1.15
+3.60%
+0.04Today
MaxCyte last closing stock price
MetricPriceDate
Last closeUSD 1.112026-08-06
MaxCyte stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.71%USD 1.052026-07-30
1 month-13.95%USD 1.292026-07-07
3 month+31.63%USD 0.842026-05-08
Year to date-28.39%USD 1.552025-12-31
1 year-45.59%USD 2.042025-08-06
3 year-73.94%USD 4.262023-08-07
5 year-93.01%USD 15.872021-08-06
Since inception-34.36%USD 1.632019-12-30

MaxCyte Financials at a Glance

Market Cap

$118.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$32.29M

Net Income (TTM)

-$39.12M

EPS (TTM)

-$0.37

P/E Ratio

-3.03

Dividend

$0.00

Beta (Volatility)

1.46 (Average)

Price

$1.15

Volume

55,840.681

Open

$1.12

Previous Close

$1.11

Daily Range

$1.12 - $1.17

52-Week Range

$0.64 - $1.87

Estimated Earnings Date

Aug 12, 2026

MXCT News

Foolcom-Featured.png

MaxCyte (MXCT) Q2 Revenue Drops 18%

Motley Fool Markets TeamAug 6, 2025
DNA sequencing genome science lab

Why Shares of MaxCyte Are Plummeting on Thursday

James HalleyOct 5, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MaxCyte

MaxCyte helps scientists and drug companies develop new cell therapies. Its machines deliver molecules into cells, making research and manufacturing easier. Hospitals and labs use these tools to create advanced treatments for diseases.

Gadgets and Gizmos: What MaxCyte Sells

  • ExPERT Instruments: Machines for moving molecules into cells; about 21% of 2025 revenue; used by labs and drug makers.
  • Processing Assemblies (PAs): Single-use kits for cell processing; 36% of 2025 revenue; needed for each experiment or production run.
  • Licenses and Support: Access to technology, regulatory help, and technical support; 27% of 2025 revenue; for research and clinical users.
  • Assay Services: Tests for gene-editing accuracy; 2% of 2025 revenue; added after acquiring SeQure Dx.
  • Consumables: Buffers and software for running machines; included in core revenue; used in every workflow.

Plot Twists: Growth and Expansion Moves

  • Acquired SeQure Dx in January 2025, adding gene-editing assessment services.
  • Launched DTx instrument in February 2026, expanding research product line.
  • Grew installed base to 857 instruments worldwide by end of 2025.
  • Expanded direct sales in North America, UK, and Europe; used distributors in Asia and parts of Europe.
  • Signed 31 active Strategic Platform Licenses (SPLs) with biopharma clients by December 2025.

Why MaxCyte Stands Out (Without Bragging)

MaxCyte’s technology lets users engineer cells without using viruses, making it flexible for research and clinical use. Its platform supports projects from small lab tests to large-scale manufacturing. The company’s recurring revenue model and regulatory support help clients move therapies from idea to market.

Five Things You Need to Know

  • Revenue was $33.0 million in 2025, down 15% from 2024.
  • Gross profit margin was 81% in 2025, slightly down from 82% in 2024.
  • Operating loss was $(51.9) million in 2025, nearly unchanged from 2024.
  • International sales made up 36% of revenue in 2025, up from 33% in 2024.
  • One customer accounted for 26% of total revenue in 2025.

Bottom Line

MaxCyte has evolved by expanding its product range and global reach. The company’s focus on cell engineering tools and services positions it as a key supplier for advanced therapy developers.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

91

CEO

Maher Masoud

Website

www.maxcyte.com

Headquarters

Rockville, MD 20850, US

MXCT Financials

Key Financial Metrics (TTM)

Gross Margin

80.70%

Operating Margin

-119.73%

Net Income Margin

-121.16%

Return on Equity

-22.03%

Return on Capital

-23.91%

Return on Assets

-20.12%

Earnings Yield

-33.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$118.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

107.12M

Volume

55.84K

Avg. Volume

1.24M

Financials (TTM)

Gross Profit

$26.06M

Operating Income

-$38.66M

EBITDA

-$34.64M

Operating Cash Flow

-$28.17M

Capital Expenditure

-$1.34M

Free Cash Flow

-$29.51M

Cash & ST Invst.

$14.56M

Total Debt

$17.49M

MaxCyte Performance Analysis

MaxCyte annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 44,261,50030.6%
20232023-12-31USD 41,288,000-6.7%
20242024-12-31USD 38,627,000-6.4%
20252025-12-31USD 33,026,000-14.5%
MaxCyte sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-18.1%
Q32025-09-30-19.7%
Q42025-12-316.9%
Q12026-03-3132.2%
MaxCyte annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.2310.1%
20232023-12-31USD -0.3758.4%
20242024-12-31USD -0.396.6%
20252025-12-31USD -0.427.1%
MaxCyte sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-20.0%
Q32025-09-30N/A
Q42025-12-3125.1%
Q12026-03-3150.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$9.65M

-7.1%

Gross Profit

$7.07M

-20.5%

Gross Margin

73.22%

N/A

Market Cap

$118.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.31M

N/A

Employees

91

N/A

Net Income

-$4.75M

+53.7%

EBITDA

-$3.70M

+58.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.56M

-89.5%

Total Debt

$17.49M

-7.1%

Accounts Receivable

$4.25M

-23.1%

Inventory

$7.63M

-7.8%

Long Term Debt

$16.11M

-8.2%

Short Term Debt

$1.37M

+7.7%

Return on Assets

-20.12%

N/A

Return on Invested Capital

-20.98%

N/A

Free Cash Flow

-$8.39M

+44.3%

Operating Cash Flow

-$8.17M

+43.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OWLTOwlet, Inc.
$5.57+2.39%
NNOXNano-X Imaging Ltd.
$1.05+2.98%
LNSRLENSAR Inc
$5.71-0.44%
TLSITriSalus Life Sciences, Inc.
$5.28+8.32%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$124.81+0.09%
TTDThe Trade Desk
$14.13-0.20%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.75+0.02%
INTCIntel
$99.66-0.00%

Questions About MXCT

What is the current price of MaxCyte?

MaxCyte is trading at $1.15 per share.

What is the 52-week range for MaxCyte?

Over the past 52 weeks, MaxCyte has traded between $0.64 and $1.87.

How much debt does MaxCyte have?

As of the most recent reporting period, MaxCyte reported total debt of $17.49M.

How much cash does MaxCyte have on hand?

MaxCyte reported $14.56M in cash and cash equivalents in its most recent financial results.

What is MaxCyte’s dividend yield?

MaxCyte does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services